Trading Signals: CYDY Stock Price Prediction and Forecast (Tue. Jul. 21, 2020 - Tue. Feb. 14, 2023)(CytoDyn Inc. )
| CYDY latest price $5.2900 (-2.4%) ($5.1800 - $5.3300) on Fri. Feb. 19, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 12.26% (three month average) | RSI | 62 | Latest Price | $5.2900(-2.4%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | CYDY declines -3.1% a day on average for past five trading days. | Weekly Trend | CYDY advances 0.8% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support CYDY advance at 0% a week (0% probability) VT(22%) XLC(14%) XAR(27%) SMH(36%) XLU(28%) | Factors Impacting CYDY price | CYDY will decline at least -6.13% in a week (0% probabilities). XRT(-39%) INDA(119%) IWC(-59%) IWO(-58%) JETS(-55%) | | | | | Relative Volatility | | | | Market Trend Strength | -6.13% (StdDev 12.26%) | Hourly BBV | 0 () | Intraday Trend | -0.6% | | | |
|
Resistance Level | $5.56 | 5 Day Moving Average | $5.67(-6.7%) | 10 Day Moving Average | $5.84(-9.42%) | 20 Day Moving Average | $5.56(-4.86%) | To recent high | -21.6% | To recent low | 2.9% | Market Cap | $2.745b | | | | CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, cancer, graft-versus-host disease (GVHD), and PCa test. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA. |